Early Propranolol After Traumatic Brain Injury: Phase II
Overview
The primary objective of this study is to determine in patients with traumatic brain injury (TBI) the safe dosing of propranolol. Safety will be measured by episodes of bradycardia (heart rate < 60 beats per minute), hypotension (defined as systolic blood pressure < 90) or decreased cerebral perfusion pressure (defined as CPP less than 60mmHg) that are refractive to Brain Trauma Foundation guidelines for treatment. A no-treatment arm will establish the number of episodes of bradycardia, hypotension and reduced cerebral pressure refractory to treatment that occur without propranolol.
Full Title of Study: “A Phase II, Dose Escalation, Single Center Study on the Effects of Early Propranolol on Heart Rate, Blood Pressure, and Cerebral Perfusion Pressure in Subjects Who Present With Moderate to Severe Traumatic Brain Injury.”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: February 2015
Interventions
- Drug: Propranolol
Arms, Groups and Cohorts
- Experimental: Propranolol
- Propranolol 1mg iv
- No Intervention: Control
- Routine care
Clinical Trial Outcome Measures
Primary Measures
- Determine in Patients With Traumatic Brain Injury (TBI) the Safe Dosing of Early Propranolol.
- Time Frame: 24 months
- The primary outcome is to determine the safety of early propranolol treatment after TBI by recording the number of episodes of bradycardia (heart rate < 60 beats per minute), hypotension (defined as systolic blood pressure < 90) or decreased cerebral perfusion pressure (defined as CPP less than 60mmHg) refractive to treatment.
Participating in This Clinical Trial
Inclusion Criteria
- patients who present within 6 hours of traumatic brain injury who have 1) a Glasgow Coma Scale (GCS) score of ≤8 or a GCS of 9-12 with computerized tomography brain scans demonstrating brain injury. Exclusion Criteria:
- pregnancy, – patients already treated with beta-blockers, – patients treated for antiarrhythmic, immunosuppressive or antiinfective treatment, – myocardial infarction during the last 3 months, – unstable or severe heart disease, – severe chronic obstructive pulmonary disease, – serious liver disease, – cardiac ischemia that prevents the initiation of vasopressors, – signs of cardiac arrhythmia or heart block on EKG, – ischemic limb disease that prevents the initiation of vasopressors, vasopressors at maximum dose defined as norepinephrine at 40µg/min or neosynephrine at 300µg/min.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 100 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Cedars-Sinai Medical Center
- Provider of Information About this Clinical Study
- Principal Investigator: Eric Ley, MD – Cedars-Sinai Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.